Drug intelligence / Profile preview

CS02 + placebo

Development stage: Phase 2
Lead developer: Zhongshan Hengdong Biopharmaceutical
Administration: Oral

Overview

CS02 + placebo refers to a combination arm used in clinical trials, where participants receive either the investigational drug "CS02" or a matching placebo. In the context of type 2 diabetes mellitus (T2DM), CS02 is administered as a tablet twice daily alongside metformin therapy. The specific identity, mechanism of action, and developer of CS02 are not disclosed in public sources; it is referenced only by its code name in clinical trial registries. The "+ placebo" indicates this is not a fixed-dose combination product but rather describes the design of comparative arms within a study[1].

Beyond the preview

Go deeper on CS02 + placebo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS02 + placebo.

Explore the full profile